The FDA's insider view on Aerie’s glaucoma drug: Yes on efficacy, but…
The FDA had some encouraging words for Aerie’s new glaucoma drug Rhopressa, but there’s a significant caveat that might come back to haunt the biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
